We read with great interest the recent paper by Siniscalchi et al. [1] in which they described a 69-year-old woman with a cutaneous relapse of multiple myeloma (MM) after six cycles of MPT regimen (melphalan, prednisone, and thalidomide) and thalidomide maintenance therapy. They reported a complete response after four cycles of bortezomib (B) and dexamethasone, suggesting a possible employment in cutaneous plasmacytomas.
Gozzetti, A., Defina, M., Bocchia, M. (2009). Cutaneous myeloma and bortezumib. ANNALS OF HEMATOLOGY, 88(10), 1045-1045 [10.1007/s00277-009-0786-7].
Cutaneous myeloma and bortezumib
GOZZETTI A.;BOCCHIA M.
2009-01-01
Abstract
We read with great interest the recent paper by Siniscalchi et al. [1] in which they described a 69-year-old woman with a cutaneous relapse of multiple myeloma (MM) after six cycles of MPT regimen (melphalan, prednisone, and thalidomide) and thalidomide maintenance therapy. They reported a complete response after four cycles of bortezomib (B) and dexamethasone, suggesting a possible employment in cutaneous plasmacytomas.File | Dimensione | Formato | |
---|---|---|---|
86090_UPLOAD.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
38.97 kB
Formato
Adobe PDF
|
38.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/3950
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo